Open access · CC-BY
via OpenAlex
Neuroimmune Dysregulation as a Public Health Axis in Neurodegeneration: Decoding Immune Checkpoints, Aging, and Biomarkers in Preclinical Alzheimer's Disease
Biomedical Research and Therapy · 2026
Abstract
Alzheimer’s Disease (AD), the leading cause of dementia globally, is increasingly recognized as a multifactorial disorder in which neurodegeneration intersects with systemic immune aging. While classical models emphasize amyloid-β and tau accumulation, accumulating evidence suggests that neuroimmune dysregulation may play a critical role during the earliest, preclinical stages of disease development. This review synthesizes emerging literature on how immune aging, immune checkpoint signaling, and biomarker discovery converge to shape early AD pathophysiology. Age-associated immune remodeling including T-cell exhaustion, impaired antigen presentation, and altered innate immune responses can disrupt central nervous system immune surveillance. In particular, dysregulated signaling through checkpoint molecules such as Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte Associated Protein 4 may influence microglial activation states, peripheral immune infiltration, and neuroinflammatory cascades that precede overt neurodegeneration. Advances in neuroimmunology and biomarker technologies including cerebrospinal fluid immune profiling, peripheral immunophenotyping, and molecular neuroimaging are beginning to reveal measurable neuroimmune signatures associated with early disease states. However, important challenges remain regarding biomarker specificity, translational feasibility, and implementation across diverse healthcare systems. By integrating insights from immunology, neuroscience, and public health research, this review proposes that neuroimmune dysfunction represents a trackable component of early AD pathogenesis. Understanding how immune aging interacts with neurodegenerative pathways may help inform future strategies for early risk stratification and preventative intervention.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.15419/bmrat.v13i6.1078
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Mukherjee, A. (2026). Neuroimmune Dysregulation as a Public Health Axis in Neurodegeneration: Decoding Immune Checkpoints, Aging, and Biomarkers in Preclinical Alzheimer's Disease. <em>Biomedical Research and Therapy</em>. https://doi.org/10.15419/bmrat.v13i6.1078
Vancouver
Mukherjee A. Neuroimmune Dysregulation as a Public Health Axis in Neurodegeneration: Decoding Immune Checkpoints, Aging, and Biomarkers in Preclinical Alzheimer's Disease. Biomedical Research and Therapy. 2026. doi:10.15419/bmrat.v13i6.1078.
BibTeX
@article{arpita2026Neuroi,
title = {Neuroimmune Dysregulation as a Public Health Axis in Neurodegeneration: Decoding Immune Checkpoints, Aging, and Biomarkers in Preclinical Alzheimer's Disease},
author = {Arpita Mukherjee},
journal = {Biomedical Research and Therapy},
year = {2026},
doi = {10.15419/bmrat.v13i6.1078},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Cellular and Infection Microbiology 2026
Open access · CC-BY
Host–virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective
Frontiers in cellular and infection microbiology 2026
Open access · OA
Host-virus resilience networks and viral inflammaging circuits in aging and long COVID: a CMV-centered perspective.
Frontiers in Neuroscience 2017
Open access · CC-BY
Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
FASEB bioAdvances 2026
Open access · OA
Retrotransposons in Bone and Joint Diseases.
Annals of the New York Academy of Sciences 2000
Citation only
A “Protease Activation Cascade” in the Pathogenesis of Alzheimer's Disease
Elsevier eBooks 2026
Citation only